This promotional material is intended for UK healthcare professionals (HCPs) experienced in the diagnosis and management of migraine only. Prescribing Information and adverse event reporting information can be found below.
.png){kind=logo}
Preventative treatment plans should consider the individual needs of patients with migraine2
According to the 2019 British Association for the Study of Headache guidelines, patients who experience ≥4 migraine days/month should be offered preventative treatment as an option, as this frequency of migraine is associated with significant disability.2
Prescribing decisions should take into account a patient’s current clinical situation as well as their future plans2
When choosing a preventative treatment, factors to consider include:2
Previous treatment
Personal preferences
Medical and other
comorbidities
Side effect profiles of various treatments
Pregnancy or contraception
AQUIPTA® is not recommended during pregnancy.1
Introducing AQUIPTA®: an oral, once‑daily CGRP receptor antagonist for migraine prevention1,3
AQUIPTA® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days/month. It is a selective CGRP receptor antagonist that blocks the binding of CGRP to the receptor and antagonises CGRP receptor function. By blocking the CGRP‑receptor interaction, AQUIPTA® prevents migraine attacks.1
CGRP levels at rest
Adapted from Schuster N M et al. 20164
CGRP levels during a migraine attack
Adapted from Schuster N M et al. 20164
During a migraine attack, levels of the neuropeptide increase.5,6 In the trigeminovascular system, CGRP modulates nociceptive signalling and inflammation, and also functions as a vasodilator,1 inducing pain, inflammation and vasodilation.7
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) GUIDANCE8
AQUIPTA® is recommended by NICE as an option for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventive medicines have not worked, or are not tolerated or are unsuitable because of safety concerns.8
Stop AQUIPTA® after 12 weeks if the frequency of migraines does not reduce by:8
> At least 50% in episodic migraine (defined as fewer than 15 headache days per month)
> At least 30% in chronic migraine (defined as 15 or more headache days per month, with at least 8 of those having features of migraine)
SCOTTISH MEDICINES CONSORTIUM
(SMC) GUIDANCE9
AQUIPTA® is accepted by SMC for restricted use within NHS Scotland for the prophylaxis of migraine in adults who have at least 4 migraine days per month.9
SMC restriction: for patients with chronic and episodic migraine who have had prior failure on three or more migraine preventative treatments.9
AQUIPTA® provides an additional treatment choice in the therapeutic class of CGRP inhibitors.9
WANT TO KNOW MORE ABOUT THE EFFICACY OF AQUIPTA® IN SPECIFIC TYPES OF MIGRAINE?
CGRP: calcitonin gene-related peptide; NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium.
References:
- AQUIPTA® Summary of Product Characteristics.
- British Association for the Study of Headache (BASH). National headache management system for adults 2019. Available at: https://bash.org.uk/wp-content/uploads/brizy/custom_files/01_BASHNationalHeadache_Management_SystemforAdults_2019_guideline_versi.pdf. Accessed November 2025
- Moreno-Ajona D, Villar-Martínez M D, Goadsby P J. New generation gepants: migraine acute and preventive medications. J Clin Med 2022;11(6):1656
- Schuster N M, Rapoport A M. New strategies for the treatment and prevention of primary headache disorders. Nat Rev Neurol. 2016;12(11):635–650
- Rivera-Mancilla E, Villalón C M, Maassen van den Brink A. CGRP inhibitors for migraine prophylaxis: a safety review. Expert Opin Drug Saf. 2020;19(10):1237–1250
- Ferrari M D, Goadsby P J et al. Migraine. Nat Rev Dis Primers 2022;8(1):2
- Goadsby P J, Holland P R et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622
- National Institute for Health and Care Excellence (NICE). Technology appraisal guidance 973. Atogepant for preventing migraine, 15 May 2024. Available at: https://www.nice.org.uk/guidance/ta973. Accessed November 2025
- Scottish Medicines Consortium (SMC). SMC2599 Atogepant (Aquipta). Available at: https://scottishmedicines.org.uk/medicines-advice/atogepant-aquipta-abbreviated-smc2599/. Accessed November 2025
Please refer to the AQUIPTA® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The AQUIPTA® Summary of Product Characteristics can be found here.
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
UK-AQP-250451 | Date of preparation: November 2025.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
